Introduction {#sec1_1}
============

Currently, the prevailing notion of the metabolic syndrome (MetS) is that it is characterized by a cluster of risk factors for atherosclerosis and type 2 diabetes mellitus and can be regarded as a physiological and clinical entity \[[@B1]\]. The main components of MetS are accumulation of intra-abdominal fat, impaired metabolism of glucose, atherogenic dyslipidemia (low high-density lipoprotein cholesterol (HDL-C), hypertriglyceridemia), and arterial hypertension. In pathogenesis, several mechanisms were shown to take part, namely insulin resistance, chronic low-grade inflammation, endothelial dysfunction, and oxidative stress; their interactions have not been fully elucidated at present. Elevated levels of oxidative stress in subjects with MetS were demonstrated in many experimental and clinical studies \[[@B2]\].

Oxidative stress is defined as an imbalance between the production of reactive oxygen and nitrogen species (RONS) and their insufficient decomposition by the antioxidant system which results in macromolecular damage and disruption of redox signaling and control \[[@B3]\]. Free radicals and non-radical oxidants belong to RONS. Free radicals could induce DNA mutations, structural disorders in proteins, and peroxidative damage of cell membrane and plasma lipids \[[@B4]\]. RONS play an important role in the pathogenesis of many cardiovascular and neurodegenerative diseases as well as in type 2 diabetes mellitus and its complications \[[@B5]\].

The defense mechanisms of the human body against oxidative stress are complex and involve cellular and extracellular antioxidant systems which are regulated at multiple levels \[[@B6]\]. Various enzymes, e.g. superoxide dismutase (CuZnSOD), glutathione peroxidase 1 (GPX1), catalase (CAT), paraoxonase 1 (PON1), glutathione reductase (GR), as well as nonenzymatic antioxidant compounds (e.g. metal chelators, low-molecular-weight antioxidants) take part in the antioxidant defense.

In the first step of the defense mechanism against superoxide anions (O~2~ ^−^), the enzyme CuZnSOD catalyzes their dismutation into oxygen and H~2~O~2~. In the second step, CAT and GPX1 independently convert H~2~O~2~ to water. Any increase in the CuZnSOD catalytic activity produces an excess of H~2~O~2~ that must be efficiently neutralized by either CAT or GPX1; otherwise, H~2~O~2~ reacts with O~2~ ^−^ producing in a two-step reaction (the Haber-Weiss reaction) hydroxyl radicals OH which are even more dangerous \[[@B5]\]. Cytosolic GPX1 detoxifies H~2~O~2~ in the presence of reduced glutathione (GSH), which is oxidized to oxidized glutathione (GSSG) and subsequently recycled by GR. GPX1 with the aid of GSH protects lipids against peroxidation. The pool of GSH has to be replenished by de novo synthesis that is catalyzed by the enzyme glutamate-cystein ligase. The PON1 enzyme as HDL-associated enzyme is implicated in the anti-inflammatory and antioxidant activities of HDL and impedes oxidative modification of low-density lipoprotein (LDL) thus protecting cell membranes from the damage caused by products of lipoperoxidation \[[@B7]\].

This study is focused on the state of the antioxidant defense system in patients with MetS. We intend to investigate the wide variety of known antioxidants in association with MetS. The activities of several antioxidant enzymes as well as the concentration of GSH were determined in the erythrocytes. It has been noted that these cells maintain fairly constant concentrations of enzymes throughout the life span which had been synthesized during the maturation of erythroid precursors \[[@B8]\]. Furthermore, levels of albumin, bilirubin, and calculated total peroxyl radical trapping (cTRAP) were assessed in serum. As a global marker of systemic oxidative stress, conjugated dienes in precipitated low-density lipoproteins (CD-LDL) were determined.

Participants and Methods {#sec1_2}
========================

Participants {#sec2_1}
------------

40 Caucasian subjects with MetS (20 male / 20 female) were recruited from outpatients who had been subsequently examined (from January 2008 until August 2010) at the Lipid Clinic of the 4th Department of Medicine, First Faculty of Medicine, Charles University in Prague. This study group was compared with a control group constituted from 40 volunteers without MetS matched for sex and age (20 male / 20 female), all Caucasian.

MetS was diagnosed according to the International Diabetes Federation criteria \[[@B9]\]. To be included, patients had to have central obesity (waist circumference ≥ 94 cm for men and ≥ 80 cm for women) and fulfill any two of the following four criteria: i) raised TG level (≥1.7 mmol/l), ii) reduced HDL-C (ℋ1.03 mmol/l in males and ℋ1.29 mmol/l in females) or specific treatment for these abnormalities, iii) raised blood pressure (BP) with systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension, and iv) raised fasting plasma glucose (≥5.6 mmol/l) or previously diagnosed type 2 diabetes mellitus. All samples were marked with unique anonymized identification numbers, and the data was merged only after the assays had been completed.

In the MetS group, 21 patients (52.5%) had three, 13 patients (32.5%) four, and 6 patients (15.0%) had all five of the above mentioned components of MetS. In the control group, only three subjects (7.5%) met two components of MetS, 15 (37.5%) controls met one, and the 22 (55.0%) volunteers showed no components of MetS. In the MetS group, 35 patients suffered from hypertension, and of these patients, 21 were under antihypertensive treatment. Among them, 12 were treated with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor type 1 blockers, and the 9 remaining subjects were on a combination of ACE inhibitor with calcium channel blockers.

Exclusion criteria for both groups were the following: current antioxidant therapy, excessive alcohol consumption (\>30 g/day), hormonal replacement therapy, supplementation with polyunsaturated fatty acids, manifestation of cardiovascular and/or cerebrovascular diseases, type 1 diabetes mellitus, liver (with exception of nonalcoholic fatty liver disease) and kidney diseases (creatinine \>130 µmol/l), microalbuminuria (urinary albumine 30--300 mg/day), hypothyroidism as well as recent infections and malignancies.

Informed consent was obtained from all participants. The study protocol was approved by the Ethical Committee of the First Faculty of Medicine, Charles University in Prague.

Blood Samples {#sec2_2}
-------------

Blood samples were collected after a 12-hour overnight fast. Activities of antioxidant enzymes (with exception of PON1) and concentrations of GSH were measured in hemolysed erythrocytes which had been separated from the EDTA plasma and washed three times with saline. Serum was used for all other parameters. Samples were stored at −80 °C until the assay.

Methods {#sec2_3}
-------

Activities of antioxidant enzymes were measured spectrophotometrically using kinetic methods previously described \[[@B10]\]. Briefly, the activity of GPX1 was measured using tert-butyl hydroperoxide as a substrate, and the rate of NADPH degradation was monitored. The molar extinction coefficient of NADPH (6,220 mol/l/cm) was used for calculation of activity which was then expressed as U/g hemoglobin. The activity of GR was measured by monitoring the rate of NADPH degradation. Activity was calculated using the molar extinction coefficient of NADPH and expressed as U/g hemoglobin. The CAT activity was calculated using the molar extinction coefficient of H~2~O~2~ (43.6 mol/l/cm), whose degradation rate was monitored at 240 nm. Activity is expressed as kU/g hemoglobin. The method of CuZnSOD activity assessment is based on the monitoring of the rate of NBT-formazan generation. Superoxide dismutase activity was calculated by means of a calibrating curve; superoxide dismutase standard (Cat. No. S9636-1kU) was purchased from Sigma Aldrich (St. Louis, MO, USA). Activity was expressed as U/g hemoglobin. The arylesterase activity of PON1 was measured using phenylacetate as a substrate. Arylesterase activity of PON1 was calculated using the molar extinction coefficient of the produced phenol (1,310 mol/l/cm) and expressed as U/ml serum.

GSH was assessed by the modified spectrophotometric method according to Griffith \[[@B11]\]; this method is based on the determination of the relatively stable product of the reduction of 5,5′ dithiobis-2-nitrobenzoic acid (DTNB). The concentration of CD-LDL was assessed by the modified method of Wieland and Seidel at 234 nm \[[@B12]\]; both methods have been fully described in the previously mentioned paper \[[@B10]\].

All routine clinical tests were performed at the Institute for Clinical Biochemistry and Laboratory Diagnostics of General University Hospital in Prague: C-reactive protein (CRP) was determined by an immunoturbidimetric method using a K-ASSAY CRP kit (Kamiya Biomedical Company, Seattle, WA, USA; cv = max. 7.6%) on a Hitachi Modular analyzer (Tokyo, Japan). Copper and zinc were measured using atomic absorption spectrometry, uric acid by an enzymatic colorimetric method with the uricase-peroxidase system, and bilirubin by the 2,5-dichlorophenyldiazonium method with a Hitachi Modular analyzer. Plasma albumin was assessed by a colorimetric method using bromocresol green. Plasma concentrations of total cholesterol (TC) and triglycerides (TG) were measured by enzymatic-colorimetric methods (Boehringer, Mannheim, Germany). HDL-C was determined in the supernatant after precipitation of lipoproteins B by PTA/Mg^2+^, using the kit from the same manufacturer; LDL-C was calculated according to Friedewald\'s formula. Concentrations of apolipoproteins apo B and apo A1 were measured by the Laurell rocket electroimmunoassay using standard and specific antibodies (Behringwerke, Marburg, Germany). The concentrations of insulin and C-peptide were determined with an electrochemiluminescence immunoassay (Roche, Basel, Switzerland). The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as HOMA-IR = (fasting serum glucose (mmol/l) × fasting serum insulin (μU/ml)) / 22.5 \[[@B13]\]. The TRAP was calculated according to the formula: (0.63 (albumin) + 1.02 (uric acid) + 1.50 (bilirubin)) \[[@B14]\].

Statistical Analysis {#sec2_4}
--------------------

Data was expressed as mean and standard deviation or median (25th-75th percentile) for data different from normal distribution. Normality of the distribution was tested by the Shapiro-Wilks W test. Comparisons between the groups were carried out by the independent t-test. Mann-Whitney U test was used for nonparametric comparisons and Spearman correlation coefficients for correlation analyses. All analyses were performed using version 8.0 of StatSoft Statistica software (2007, Czech version). The p value ℋ 0.05 was considered statistically significant.

Results {#sec1_3}
=======

Clinical and biochemical characteristics of the group of subjects with MetS and that of healthy controls are shown in table [1](#T1){ref-type="table"}. The groups did not differ in age. In both groups there were no subjects with either type 1 or type 2 diabetes mellitus. The subjects included in the MetS group suffer from insulin resistance when the metabolism of glucose was impaired.

As expected, subjects with MetS had significantly higher values of body mass index and waist circumference. They also had higher values of systolic BP and diastolic BP, glucose, TC, TG, apolipoprotein B (apo B), and uric acid as well as a higher level of insulin and insulin resistance, as assessed by the homeostatic model HOMA-IR. Decreased values were observed for plasma concentrations of HDL-C and apo A1. The difference in CRP did not reach statistical significance. As expected, men have decreased levels of HDL-C and Cu and increased values of waist circumference compared to women.

Activities of antioxidant enzymes and concentrations of GSH and CD-LDL together with levels of cTRAP are presented in table [2](#T2){ref-type="table"}. In the group of subjects with MetS, activities of CuZnSOD and GR as well as concentrations of CD-LDL and levels of cTRAP were significantly elevated. On the other hand, activities of CAT and PON1 as well as concentrations of GSH were found to be decreased.

Spearmen correlations (after Bonferroni adjustment) between selected variables are shown in table [3](#T3){ref-type="table"}. All risk factors of MetS correlated significantly with the number of components of MetS, namely abnormal levels of glucose, waist circumference, TG, HDL-C, and SBP. Concentrations of CD-LDL significantly correlated with concentrations of TG and HDL-C.

Activities of CuZnSOD correlated positively with those of GR (r = 0.341, p ℋ 0.01) and GPX1 (r = 0.260, p ℋ 0.05), and with concentrations of Zn (r = 0.363, p ℋ 0.01) as well as negatively with the ratio Cu/Zn (r = −0.278, p ℋ 0.05). Activities of PON1 correlated positively with apo A1 (r = 0.479, p ℋ 0.001). Concentrations of CD-LDL correlated positively with TC (r = 0.565, p ℋ 0.001), apo B (r = 0.597, p ℋ 0.001), and LDL-C (r = 0.384, p ℋ 0.001), and negatively with CAT (r = −0.233, p ℋ 0.05).

Discussion {#sec1_4}
==========

In this study, comparing MetS patients with an age- and sex-matched control group, increased activities of CuZnSOD (+15%, p ℋ 0.05) and GR (+19%; p ℋ 0.001) and increased levels of CD-LDL (+14.4%; p ℋ 0.001) and cTRAP (+6.5%; p ℋ 0.01) were found in MetS patients. In contrast, activities of CAT (−7.3%; p ℋ 0.05) and PON1 (−11.7%; p ℋ 0.05) as well as serum concentration of GSH (−61%; p ℋ 0.05) were significantly decreased. The HOMA-IR demonstrated evidence of a significantly increased insulin resistance in subjects with MetS.

Under resting physiological conditions, biologic systems generate only small amounts of the superoxide anion. Its overproduction can result from mitochondrial electron leakage in hyperglycemia \[[@B15]\]. Other causes of superoxide overproduction are increased activities of NAD(P)H oxidases \[[@B16]\], xanthine oxidase, lipoxygenase, and cyclooxygenase as well as an imbalance in the thioredoxin system \[[@B17]\]. Large amounts of superoxide and other RONS arise in the accumulated fat, mainly due to increased activities of NAD(P)H oxidases and a decreased expression of antioxidant enzymes \[[@B18]\]. Adipose tissue is an important generator of oxidative stress and inflammation, contributing to the production of pro-inflammatory cytokines (TNFα, IL-1, IL-6 etc.). Oxidative stress is supposed to worsen the inflammatory state in MetS via activation of redox-sensitive transcription factors (particularly NFκB) by RONS, inducing the expression of TNFα and IL-6. These cytokines increased CRP synthesis. However, in our study, we did not find a statistically significant difference in CRP levels between MetS patients and controls. This could be caused by the method used for CRP measurement. The method used in our study lacks the sensitivity to differ between low-grade inflammation in MetS (CRP between 1.0 and 3 mg/l) and subjects without MetS (CRP ℋ 1.0 mg/l).

The raised CuZnSOD activities in the erythrocytes of patients with MetS found in our study may be compared with the results of Mitrijevic-Sreckovic et al. \[[@B19]\], who described slightly increased CuZnSOD activities in children with MetS in comparison with obese children without MetS. Studies on serum CuZnSOD activities did not show consistent results \[[@B20],[@B21]\]. Increased CuZnSOD activity results in raised amounts of H~2~O~2~ which becomes toxic when activity of CAT is normal or decreased. Induction of one enzyme (CAT or CuZnSOD) does not necessarily lead to the induction of the other one \[[@B22]\]. Another source of H~2~O~2~ is its passage through the erythrocyte membrane \[[@B23]\]. The elevated production of ROS in the endothelium could thus lead to increased levels of ROS also in erythrocytes.

In our study, we have found a significantly decreased activity of CAT. Because of the increased activity of CuZnSOD in our study, elevated levels of H~2~O~2~ have to be expected. According to study of Kirkman et al. \[[@B24]\], during lengthy exposure of CAT to H~2~O~2~, the CAT-bound NADPH became oxidized to NADP^+^ and activity of CAT fell to about one third of the initial activity. Consequently, the cause of the decrease of CAT activity could be the damage of erythrocyte CAT by H~2~O~2~. Contrary to our study, Cardona et al. \[[@B20],[@B21]\] found increased activities of CAT in patients with hypertriglyceridemia (concentration of TG \> 1.7 mmol/l) apart from the presence of MetS, and these activities were further increased after fat overload. Decreased activities of CAT were described in patients bearing only individual components of MetS -- obesity \[[@B25]\], hypertension \[[@B26]\], or insulin resistance \[[@B27]\]. Decreased activity of CAT implies stressed condition of erythrocytes when complete removal of H~2~O~2~ is not possible \[[@B28]\]. Low activities of CAT were associated with an increased risk of diabetes mellitus and its complications \[[@B5],[@B29]\].

The GPX1 activity in our study was not altered in MetS patients. This result is in accordance with the study of Mitrijevic-Sreckovic \[[@B19]\]. On the contrary, Cardona et al. \[[@B20],[@B21]\] found lower activities of GPX1 in a group of subjects with hypertriglyceridemia, a part of MetS presence, and the drop of its activity was almost to 75% of that of the control group. Bougoulia et al. \[[@B30]\] showed decreased activity of GPX1 in obese subjects as well as an increase after weight reduction.

As expected, concentrations of GSH were significantly decreased and activities of GR increased in our group of subjects with MetS. Decreased concentrations of GSH with opposite changes in GSSG levels were also found in MetS subjects in the study of Cardona et al. \[[@B20]\]. On the other hand, Cardona et al. \[[@B21]\] registered a significant drop in GR activity in MetS subjects. Increased activity of GR could be attributed to a compensatory protective mechanism of the cells against ROS. Furthermore, our expected increase in the GSSG/GSH ratio due to lower levels of GSH may stimulate compensatory increase in GR activity in blood to reduce higher levels of GSSG into GSH \[[@B31]\].

The finding of decreased arylesterase activities of PON1 in our subjects with MetS is in accordance with other studies \[[@B32],[@B33]\]. Because it was shown \[[@B34]\] that there is a strong positive correlation between arylesterase and paraoxonase activity of PON1, we could therefore discuss arylesterase and paraoxonase activity of PON1 together. Low activities of PON1 have been shown to be associated with oxidative stress, hypercholesterolemia, diabetes mellitus, cardiovascular diseases, and sepsis \[[@B34],[@B35]\].

In the present study, we found significantly higher concentrations of CD-LDL in subjects with MetS. This test was shown to be the most sensitive indicator of lipid peroxidation and can be regarded as a global marker of systemic oxidative stress \[[@B36]\]. In this study, several anthropometric and biochemical characteristics of MetS correlated significantly with increased concentrations of CD-LDL, which reflect oxidation of the lipid component of LDL. This finding is in agreement with the results of our studies concerning the severity of MetS, oxidative stress, hypertriglyceridemia, and fatty acid metabolism \[[@B37],[@B38]\]. The important role of lipid peroxidation in the pathogenesis of MetS has been proven in many experimental and clinical studies \[[@B39]\].

Conclusion {#sec1_5}
==========

In the present study, we estimated a wide variety of antioxidant enzymes, and activities of several enzymes were changed in subjects with MetS. Enzyme activities were assessed in the erythrocytes where the concentration of enzymes remain stable throughout the life span and reflect adaptive changes in their expression in erythroid precursors. According to our results, alterations of antioxidant enzymes related to MetS are not uniform. While activities of CuZnSOD and GR were higher in the MetS group than in healthy subjects, a decrease in CAT and PON1 as well as the absence of the expected increase in GPX1 indicate a disorder in antioxidant defense mechanisms. Our results could be interpreted that the erythrocytes and their GSH levels and activities of GR and GPX1 protect against oxidative stress in MetS. The severity of MetS, as assessed by the number of its components, significantly correlated with the concentrations of CD-LDL.
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###### 

Clinical and biochemical characteristics of subjects with the metabolic syndrome and of healthy controls[^a^](#T1F1){ref-type="table-fn"}

                        Metabolic syndrome                                     Controls                                                                                                                                       
  --------------------- ------------------------------------------------------ ----------------------------------------------------- ---------------------------------------------------- ---------------- ------------------ ----------------
  N                     40                                                     20                                                    20                                                   40               20                 20
  Age, years            58.4                                                   57.0                                                  58.7                                                 58.5             57.8               59.5
                        (53.4--62.2)                                           (50.1--63.1)                                          (55.9--61.6)                                         (52.6--64.5)     (50.1--64.0)       (54.0--65.0)
  Waist, cm             101.4 ± 9.1[\*\*\*](#T1F4){ref-type="table-fn"}        104.4 ± 6.4[\*\*\*](#T1F4){ref-type="table-fn"}+      98.3 ± 10.5[\*\*\*](#T1F4){ref-type="table-fn"}      82.5 ± 11.0      86.9 ± 13.2^+^     78.3 ± 6.6
  BMI, kg/m^2^          29.4                                                   29.0                                                  30.6                                                 23.9             25.0               23.8
                        (27.4--31.7)[\*\*\*](#T1F4){ref-type="table-fn"}       (27.7--30.3)[\*\*](#T1F3){ref-type="table-fn"}        (25.9--32.4)[\*\*\*](#T1F4){ref-type="table-fn"}     (21.9--25.5)     (21.8--26.3)       (21.9--25.4)
  Smoking, N (%)        10 (25.0)                                              6 (30.0)                                              4 (20.0)                                             4 (10.0)         0 (0.0)            4 (20.0)
  Hypertension, N (%)   35 (87.5)                                              18 (90.0)                                             17 (85.0)                                            8 (20.0)         5 (25.0)           3 (15.0)
  Systolic BP, mm Hg    140                                                    140                                                   140                                                  130              128                130
                        (130--143)[\*\*](#T1F3){ref-type="table-fn"}           (130--140)[\*\*\*](#T1F4){ref-type="table-fn"}        (130--145)                                           (120--130)       (120--130)         (120--140)
  Diastolic BP, mm Hg   90 (88--95)[\*\*\*](#T1F4){ref-type="table-fn"}        90 (90--95)[\*\*\*](#T1F4){ref-type="table-fn"}       90 (83--95)[\*\*\*](#T1F4){ref-type="table-fn"}      80 (80--80)      80 (80--85)        80 (80--85)
  Glucose, mmol/l       5.4 (4.8--6.1)[\*\*\*](#T1F4){ref-type="table-fn"}     5.0 (4.7--5.8)                                        5.6 (5.1--6.3)[\*\*](#T1F3){ref-type="table-fn"}     4.7 (4.5--5.1)   4.9 (4.5--5.4)     4.7 (4.3--5.0)
  Insulin, mU/l         11.4 (8.7--14.8)[\*\*\*](#T1F4){ref-type="table-fn"}   11.4 (8.6--15.1)[\*\*](#T1F2){ref-type="table-fn"}    11.3 (9.4--14.3)[\*\*](#T1F2){ref-type="table-fn"}   7.8 (4.6--9.5)   8.5 (4.8--10.1)    7.6 (4.6--9.1)
  C-peptid, nmol/l      0.97                                                   0.99                                                  0.93                                                 0.64             0.59               0.68
                        (0.84--1.19)[\*\*\*](#T1F4){ref-type="table-fn"}       (0.86--1.14)[\*\*\*](#T1F4){ref-type="table-fn"}      (0.81--1.28)[\*\*\*](#T1F4){ref-type="table-fn"}     (0.51--0.75)     (0.46--0.75)       (0.55--0.73)
  HOMA-IR               3.0 (1.9--3.8)[\*\*\*](#T1F4){ref-type="table-fn"}     3.0 (1.8--3.7)[\*\*](#T1F2){ref-type="table-fn"}      3.0 (2.1--4.5)[\*\*](#T1F3){ref-type="table-fn"}     1.6 (1.0--2.1)   1.8 (1.0--2.2)     1.6 (1.0--1.9)
  TC, mmol/l            6.3 (5.2--7.3)[\*\*](#T1F2){ref-type="table-fn"}       6.2 (5.2--7.1)[\*\*](#T1F2){ref-type="table-fn"}      6.5 (5.2--7.4)                                       5.7 (5.0--6.2)   5.7 (4.8--6.1)     5.8 (5.0--6.6)
  TG, mmol/l            2.6 (1.9--3.7)[\*\*\*](#T1F4){ref-type="table-fn"}     2.3 (1.9--3.6)[\*\*](#T1F3){ref-type="table-fn"}      2.7 (1.7--3.9)[\*\*\*](#T1F4){ref-type="table-fn"}   1.1 (0.9--1.4)   1.1 (0.8--1.4)     1.0 (0.9--1.3)
  HDL-C, mmol/l         1.2 (1.1--1.3)[\*\*\*](#T1F4){ref-type="table-fn"}     1.1 (1.0--1.2)[\*\*\*](#T1F4){ref-type="table-fn"}+   1.2 (1.1--1.3)[\*\*\*](#T1F4){ref-type="table-fn"}   1.6 (1.3--1.8)   1.5 (1.3--1.8)     1.6 (1.5--1.9)
  LDL-C, mmol/l         3.6 (3.1--4.3)                                         3.5 (3.2--4.2)                                        3.6 (3.0--4.3)                                       3.5 (2.8--4.3)   3.4 (2.9--3.8)     3.6 (2.8--4.3)
  Apo A1, g/l           1.26 ± 0.25[\*\*](#T1F3){ref-type="table-fn"}          1.24 ± 0.25                                           1.28 ± 0.26[\*\*](#T1F3){ref-type="table-fn"}        1.43 ± 0.21      1.36 ± 0.20^+^     1.50 ± 0.20
  Apo B, g/l            1.34 ± 0.32[\*\*\*](#T1F4){ref-type="table-fn"}        1.39 ± 0.26[\*\*\*](#T1F4){ref-type="table-fn"}       1.28 ± 0.37                                          1.09 ± 0.25      1.06 ± 0.22        1.13 ± 0.28
  NEFA, mmol/l          0.50                                                   0.43                                                  0.51                                                 0.55             0.59               0.55
                        (0.39--0.72)                                           (0.35--0.68)                                          (0.43--0.75)                                         (0.43--0.71)     (0.435--0.83)      (0.40--0.61)
  CRP, mg/l             2.7 (2.0--6.3)                                         2.8 (2.0--4.3)                                        2.7 (2.0--7.4)                                       2.3 (2.0--6.5)   2.0 (2.0--4.3)     4.6 (2.1--7.3)
  Cu, nmol/l            17.7                                                   17.0                                                  19.6                                                 18.5             16.3               19.9
                        (16.0--20.5)                                           (15.5--18.4)                                          (16.3--21.7)                                         (16.3--21.5)     (14.3--18.6)^++^   (18.5--23.4)
  Zn, nmol/l            16.0                                                   15.8                                                  16.3                                                 15.4             16.0               15.2
                        (13.4--17.7)                                           (13.4--17.8)                                          (13.8--17.1)                                         (14.6--19.9)     (14.5--18.3)       (14.7--20.8)
  Bilirubin, \|imol/l   9.1                                                    10.9                                                  7.2                                                  10.6             13.9               9.0
                        (6.8--12.9)                                            (7.9--13.8)^+^                                        (6.1--9.6)                                           (8.0--15.2)      (9.8--18.2)^++^    (7.5--12.3)
  Uric acid, \|imol/l   346                                                    355                                                   329                                                  293              320                251
                        (290--390)[\*\*](#T1F3){ref-type="table-fn"}           (312--420)[\*\*](#T1F2){ref-type="table-fn"}          (275--352)[\*\*](#T1F3){ref-type="table-fn"}         (236--346)       (291--370)^+++^    (195--293)

BP = Blood pressure; TC = total cholesterol; TG = triglycerides; HDL-C = high density lipoprotein; LDL-C = low density lipoprotein; Apo = apolipoprotein; HOMA-IR = homeostasis model assessment of insulin resistance; QUICKI = quantitative insulin sensitivity check index; NEFA = non-esterified fatty acids; CRP = C-reactive protein; Met = metabolic syndrome.

Data presented as mean ± standard deviation (SD) for parametric and median (IQR) for non-parametric variables;

MetS versus controls: p \<0.05

p \<0.01

p \<0.001. Female versus male: +p \<0.05, ^++^p \<0.01, ^+++^p \<0.001.

###### 

Parameters of oxidative stress of studied groups

                      Metabolic syndrome                                 Controls                                                                                                                                
  ------------------- -------------------------------------------------- ----------------------------------------------------- ---------------------------------------------- ---------------- ----------------- ----------------
  GPX1, U/g Hb        59.4 ± 15.8                                        57.6 ± 18.1                                           61.1 ± 13.4                                    59.1 ± 17.7      55.4 ± 19.2       62.8 ± 15.7
  GR, U/g Hb          8.19 ± 1.54[\*\*\*](#T2F3){ref-type="table-fn"}    8.74 ± 1.21[\*\*\*](#T2F3){ref-type="table-fn"} ^+^   7.63 ± 1.67                                    6.88 ± 1.66      6.92 ± 1.76       6.83 ± 1.60
  GSH, mg/g Hb        0.57 0.56                                                                                                1.51                                           1.46             1.22              1.70
                      (0.38--2.73)[\*](#T2F1){ref-type="table-fn"}       (0.40--0.70)                                          (0.38--5.01)                                   (0.41--5.22)     (0.43--5.40)      (0.40--5.05)
  CAT, kU/g Hb        189.6 ± 31.8[\*](#T2F1){ref-type="table-fn"}       192.5 ± 27.8                                          186.7 ± 35.8                                   204.6 ± 33.0     206.1 ± 32.5      203.1 ± 34.4
  CuZnSOD, kU/g Hb    2.3 (1.9--2.5)[\*\*](#T2F2){ref-type="table-fn"}   2.3 (2.2--2.5)[\*](#T2F1){ref-type="table-fn"}        2.0 (1.7--2.5)^+^                              2.0 (1.2--2.5)   2.2 (1.1--2.6)    2.0 (1.3--2.4)
  PONI, kU/l          158.9 ± 41.9[\*](#T2F1){ref-type="table-fn"}       152.0 ± 47.4                                          165.7 ± 35.4                                   179.9 ± 42.3     170.2 ± 36.1      189.5 ± 46.5
  CD, mmol/l          61.9 57.3                                                                                                63.8                                           54.1             53.3              57.5
                      (54.1--84.3)[\*\*\*](#T2F3){ref-type="table-fn"}   (53.4--68.7)[\*](#T2F1){ref-type="table-fn"}          (55.3--94.2)[\*](#T2F1){ref-type="table-fn"}   (41.3--63.6)     (33.8--63.6)      (42.9--68.1)
  cTRAP, **n**mol/l   823 875                                                                                                  785                                            773              809               701
                      (766--877)[\*\*](#T2F2){ref-type="table-fn"}       (816--909)[\*](#T2F1){ref-type="table-fn"} ^++^       (732--835)[\*\*](#T2F2){ref-type="table-fn"}   (691--820)       (768--865)^+++^   (655--776)

GPX1 = glutathione peroxidase 1; GR = glutathione reductase; GSH = reduced glutathione; CAT = catalase; CuZnSOD = CuZn-superoxide dismutase; PON1 = paraoxonase1 -- arylesterase activity; CD = conjugated dienes in precipitated LDL; cTRAP = calculated total peroxyl radical trapping -- calculation: \[0.63 (albumin) + 1.02 (uric acid) + 1.50 (bilirubin)\]; Met = metabolic syndrome; Data presented as mean **±** standard deviation (S.D.) for parametric and median (IQR) for non-parametric variables.

MetS versus controls: p \<0.05

p \<0.01

p \<0.001. Female versus male: +p \<0.05, ++ p \<0.01, +++p \<0.001.

###### 

Spearman correlation coefficients for components of the metabolic syndrome and parameters of oxidative stress in the combined group (metabolic syndrome plus controls) (N = 80)

            SBP     TG           HDL-C         Glucose     HOMA-IR      MetSC         CD           PON1     GR         GPX1     CAT      CuZnSOD
  --------- ------- ------------ ------------- ----------- ------------ ------------- ------------ -------- ---------- -------- -------- ---------
  Waist     0.313   0.533^+++^   −0.602^+++^   0.402^++^   0.570^+++^   0.717^+++^    0.336        −0.103   0.377^+^   −0.160   −0.115   0.049
  SBP       --      0.270        −0.147        0.141       0.103        0.405^++^     0.338        −0.039   0.129      0.076    −0.108   −0.097
  TG        --      --           −0.631^+++^   0.396^+^    0.453^++^    0.736^+++^    0.571^+++^   −0.170   0.219      −0.067   −0.182   0.017
  HDL-C     --      --           --            −0.357^+^   −0.405^+^    −0.681^+++^   −0.374^+^    0.321    −0.148     0.086    0.133    −0.015
  Glucose   --      --           --            --          0.555^+++^   0.540^+++^    0.019        −0.103   0.127      −0.286   −0.081   −0.118
  HOMA-IR   --      --           --            --          --           0.493^+++^    0.099        −0.088   0.216      0.025    −0.066   −0.073
  MetSC     --      --           --            --          --           --            0.442^++^    −0.193   0.261      −0.097   −0.249   −0.115

SBP = Systolic blood pressure; TG = triglycerides; HDL-C = high density lipoprotein; HOMA-IR = homeostasis model assessment of insulin resistance; Met = metabolic syndrome; MetSC = number of components of the MetS (N = 1--5; waist circumference, glucose, triglycerides, HDL-C, SBP); GPX1 = glutathione peroxidase 1; GR = glutathione reductase; CAT = catalase; CuZnSOD = CuZn-superoxide dismutase; PON1 = paraoxonase-1-arylesterase activity; CD = conjugated dienes in precipitated LDL. +p \<0.05; ++p \<0.01; ^+++^p \<0.001; after Bonferroni adjustment.
